1/21/2013

Annual Summary of Stock Exchange Releases published in 2012

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;}

ORION CORPORATION        STOCK EXCHANGE RELEASE 21 JAN 2013 AT 10:00 a.m. EET              

In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases published by the company in 2012. The releases are available on the internet website of Orion Corporation, at http://www.orion.fi/se-releases.
Orion points out that part of the information in the releases can have become out-dated.

Stock Exchange Releases in 2012

January
20 Jan 2012 Orion invites analysts and media to Financial Statement Release conference on Tuesday 7 February 2012
20 Jan 2012 Orion Corporation: Annual Summary of Stock Exchange Releases published in 2011
30 Jan 2012 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2012 AGM of Orion Corporation
February
7 Feb 2012 Orion continues development of inhalable budesonide-formoterol combined formulation
7 Feb 2012 Orion Group Financial Statement Release for 2011
7 Feb 2012 Notice to the Annual General Meeting of Orion Corporation
March
6 Mar 2012 Orion Group Annual Report 2011 published
12 Mar 2012 Orion Corporation: Transfer of 87,763 own B-shares on 12 March 2012
20 Mar 2012 Orion Oyj : Decisions by the AGM on 20 March 2012
20 Mar 2012 Orion Oyj : Orion Corporation: Organising meeting of the Board of Directors
26 Mar 2012 Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a generic version of Orion's proprietary drug Stalevo® in the United States
April
10 Apr 2012 Orion Corporation: 300,000 Orion A-shares converted into B-shares
10 Apr 2012 Orion invites analysts and media to Q1 news conference on Tuesday 24 April 2012
24 Apr 2012 Orion Group Interim Report January-March 2012
26 Apr 2012 Orion sues Mylan in the U.S. to enforce its U.S. patents covering the proprietary drug Stalevo®
May
1 May 2012 U.S. District Court gives decision on Precedex® patent litigation
June
July
3 Jul 2012 Orion upgrades full-year outlook for 2012
5 Jul 2012 200,000 Orion A-shares converted into B-shares
16 Jul 2012 Orion invites analysts and media to Q2 news conference on Tuesday 31 July 2012
31 Jul 2012 Orion Corporation's publication schedules for financial reporting in 2013
31 Jul 2012 Orion Group Interim Report January-June 2012
August
September
5 Sep 2012 Disclosure Under Chapter 2 Section 10
5 Sep 2012 Orion Corporation: Correction to the English version of the stock exchange release
12 Sep 2012 200,000 Orion A-shares converted into B-shares
October
9 Oct 2012 Orion invites analysts and media to Q3 news conference on Tuesday 23 October 2012
9 Oct 2012 Orion upgrades full-year outlook for 2012
23 Oct 2012 Orion Group Interim Report January-September 2012
23 Oct 2012 Composition of the Nomination Committee of Orion Corporation
November
19 Nov 2012 823,000 Orion A-shares converted into B-shares
30 Nov 2012 Orion is planning to apply for a marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family
December
20 Dec 2012 203,000 Orion A-shares converted into B-shares
20 Dec 2012 Orion and Mylan settle patent dispute over the proprietary drug Comtan®

Orion Corporation

Timo Lappalainen
President and CEO
Olli Huotari
SVP, Corporate Functions

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.

 

Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.